Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics plc - American Depositary Shares (NQ:AUTL)

1.605 -0.115 (-6.69%)
Delayed Quote Updated: 1:53 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Autolus Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis
Enrollment in LUMINA, the pivotal Phase 2 study of obe-cel in refractory lupus nephritis, is ongoing 
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus (AUTL) Q2 2026 Earnings Call Transcript ↗
Revenue surged 119% year-over-year as gross margins turned positive for the first time. 
Via The Motley Fool
Topics Earnings
Autolus Therapeutics (NASDAQ:AUTL) Posts Inline Q1 Results with First Positive Gross Margin, but Full-Year Guidance Slightly Below Consensus ↗
Via Chartmill
News headline image
Autolus Therapeutics Q2 Earnings Call Highlights ↗
Autolus Therapeutics (NASDAQ:AUTL) reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier,... 
Via MarketBeat
Topics Earnings
News headline image
Autolus Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Second Quarter 2026 Financial Results and Host Conference Call on August 11, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
Top stock movements in today's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conference
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Receives Prix Galien UK Award
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus (AUTL) Q1 2026 Earnings Transcript ↗
Autolus (AUTL) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Autolus Therapeutics Q1 Earnings Call Highlights ↗
Autolus Therapeutics (NASDAQ:AUTL) reported higher first-quarter 2026 product revenue and said its commercial launch of AUCATZYL is gaining traction in the U.S. and U.K., while reiterating full-year... 
Via MarketBeat
Topics Earnings
News headline image
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
From Autolus Therapeutics plc
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
Via Investor Brand Network
Topics Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Via Investor Brand Network
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
From BioMedWire
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 27, 2026
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
Autolus Therapeutics to Participate in Upcoming Investor Conferences
From Autolus Therapeutics plc
Via GlobeNewswire
News headline image
The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Autolus Therapeutics plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.